Comparison · NCT05314517-3bf0f6d2
Namilumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the DB Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Namilumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the DB Period. Trial comparisons, record NCT05314517-3bf0f6d2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05314517-3bf0f6d2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.942 | 0.844 | 0.98 | wilson | |
| Risk in group 2 | 0.944 | 0.849 | 0.981 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00214 | -0.107 | 0.101 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.998 | 0.909 | 1.1 | log | |
| Odds ratio, group 1 over group 2 | 0.961 | 0.185 | 4.99 | log | |
| Number needed to treat, for one fewer participant with the outcome on Namilumab than on Placebo | 468 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Namilumab | Participants received namilumab SC on Day 1, Day 15 (Week 2), and then Q4W thereafter through Week 22. | 49 | 52 | OG000 |
| Group 2 | Placebo | Participants received placebo matched to namilumab dosing through Week 22. | 51 | 54 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the DB Period
- Description
An adverse event (AE) was any untoward medical occurrence in a participant administered the study drug and which did not necessarily have a causal relationship with this treatment. TEAEs are those AEs with start date on or after the start date of treatment through the earlier of 18-week post last dose during DB period or prior to first dose during OLE period, whichever was earlier. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
- Time frame
- Baseline up to Week 26
- Population
- Safety population included all randomized participants who received any amount of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
- NCT number
- NCT05314517
- Phases
- PHASE2
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Namilumab, Placebo
- Lead sponsor
- Kinevant Sciences GmbH
- Results first posted
- 2025-09-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05314517?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05314517-3bf0f6d2